Browse PSMC2

Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Note=Colocalizes with TRIM5 in cytoplasmic bodies.
Domain PF00004 ATPase family associated with various cellular activities (AAA)
Function

Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. PSMC2 belongs to the heterohexameric ring of AAA (ATPases associated with diverse cellular activities) proteins that unfolds ubiquitinated target proteins that are concurrently translocated into a proteolytic chamber and degraded into peptides.

> Gene Ontology
 
Biological Process GO:0000209 protein polyubiquitination
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0002218 activation of innate immune response
GO:0002220 innate immune response activating cell surface receptor signaling pathway
GO:0002223 stimulatory C-type lectin receptor signaling pathway
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006520 cellular amino acid metabolic process
GO:0006521 regulation of cellular amino acid metabolic process
GO:0007164 establishment of tissue polarity
GO:0007346 regulation of mitotic cell cycle
GO:0009308 amine metabolic process
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0010565 regulation of cellular ketone metabolic process
GO:0010608 posttranscriptional regulation of gene expression
GO:0016055 Wnt signaling pathway
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030433 ER-associated ubiquitin-dependent protein catabolic process
GO:0031145 anaphase-promoting complex-dependent catabolic process
GO:0031329 regulation of cellular catabolic process
GO:0031331 positive regulation of cellular catabolic process
GO:0031334 positive regulation of protein complex assembly
GO:0031349 positive regulation of defense response
GO:0031396 regulation of protein ubiquitination
GO:0031397 negative regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0033238 regulation of cellular amine metabolic process
GO:0034612 response to tumor necrosis factor
GO:0034976 response to endoplasmic reticulum stress
GO:0035567 non-canonical Wnt signaling pathway
GO:0036503 ERAD pathway
GO:0038061 NIK/NF-kappaB signaling
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042176 regulation of protein catabolic process
GO:0042180 cellular ketone metabolic process
GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043254 regulation of protein complex assembly
GO:0043487 regulation of RNA stability
GO:0043488 regulation of mRNA stability
GO:0044089 positive regulation of cellular component biogenesis
GO:0044106 cellular amine metabolic process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045732 positive regulation of protein catabolic process
GO:0045862 positive regulation of proteolysis
GO:0045898 regulation of RNA polymerase II transcriptional preinitiation complex assembly
GO:0045899 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly
GO:0048002 antigen processing and presentation of peptide antigen
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0051123 RNA polymerase II transcriptional preinitiation complex assembly
GO:0051348 negative regulation of transferase activity
GO:0051436 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
GO:0051437 positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition
GO:0051438 regulation of ubiquitin-protein transferase activity
GO:0051439 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
GO:0051443 positive regulation of ubiquitin-protein transferase activity
GO:0051444 negative regulation of ubiquitin-protein transferase activity
GO:0060070 canonical Wnt signaling pathway
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060260 regulation of transcription initiation from RNA polymerase II promoter
GO:0060261 positive regulation of transcription initiation from RNA polymerase II promoter
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061136 regulation of proteasomal protein catabolic process
GO:0065004 protein-DNA complex assembly
GO:0070897 DNA-templated transcriptional preinitiation complex assembly
GO:0071356 cellular response to tumor necrosis factor
GO:0071824 protein-DNA complex subunit organization
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090175 regulation of establishment of planar polarity
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0198738 cell-cell signaling by wnt
GO:1901800 positive regulation of proteasomal protein catabolic process
GO:1901987 regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1903050 regulation of proteolysis involved in cellular protein catabolic process
GO:1903052 positive regulation of proteolysis involved in cellular protein catabolic process
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903321 negative regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1903362 regulation of cellular protein catabolic process
GO:1903364 positive regulation of cellular protein catabolic process
GO:1904666 regulation of ubiquitin protein ligase activity
GO:1904667 negative regulation of ubiquitin protein ligase activity
GO:1904668 positive regulation of ubiquitin protein ligase activity
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
GO:2000058 regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:2000060 positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:2000142 regulation of DNA-templated transcription, initiation
GO:2000144 positive regulation of DNA-templated transcription, initiation
Molecular Function GO:0008134 transcription factor binding
GO:0016887 ATPase activity
GO:0017025 TBP-class protein binding
GO:0036402 proteasome-activating ATPase activity
GO:0042623 ATPase activity, coupled
Cellular Component GO:0000502 proteasome complex
GO:0000932 cytoplasmic mRNA processing body
GO:0005838 proteasome regulatory particle
GO:0008540 proteasome regulatory particle, base subcomplex
GO:0022624 proteasome accessory complex
GO:0031595 nuclear proteasome complex
GO:0031597 cytosolic proteasome complex
GO:0035770 ribonucleoprotein granule
GO:0036464 cytoplasmic ribonucleoprotein granule
GO:0044445 cytosolic part
GO:1905368 peptidase complex
GO:1905369 endopeptidase complex
> KEGG and Reactome Pathway
 
KEGG hsa03050 Proteasome
Reactome R-HSA-5619084: ABC transporter disorders
R-HSA-382556: ABC-family proteins mediated transport
R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-174154: APC/C
R-HSA-176409: APC/C
R-HSA-174178: APC/C
R-HSA-179419: APC
R-HSA-170984: ARMS-mediated activation
R-HSA-450408: AUF1 (hnRNP D0) binds and destabilizes mRNA
R-HSA-176814: Activation of APC/C and APC/C
R-HSA-1169091: Activation of NF-kappaB in B cells
R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-983168: Antigen processing
R-HSA-109581: Apoptosis
R-HSA-68867: Assembly of the pre-replicative complex
R-HSA-4608870: Asymmetric localization of PCP proteins
R-HSA-174084: Autodegradation of Cdh1 by Cdh1
R-HSA-349425: Autodegradation of the E3 ubiquitin ligase COP1
R-HSA-422475: Axon guidance
R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-69017: CDK-mediated phosphorylation and removal of Cdc6
R-HSA-68827: CDT1 association with the CDC6
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-174184: Cdc20
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2262749: Cellular response to hypoxia
R-HSA-2262752: Cellular responses to stress
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1236978: Cross-presentation of soluble exogenous antigens (endosomes)
R-HSA-69656: Cyclin A
R-HSA-69202: Cyclin E associated events during G1/S transition
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-69306: DNA Replication
R-HSA-69002: DNA Replication Pre-Initiation
R-HSA-5607761: Dectin-1 mediated noncanonical NF-kB signaling
R-HSA-5678895: Defective CFTR causes cystic fibrosis
R-HSA-4641257: Degradation of AXIN
R-HSA-4641258: Degradation of DVL
R-HSA-5610780: Degradation of GLI1 by the proteasome
R-HSA-5610783: Degradation of GLI2 by the proteasome
R-HSA-195253: Degradation of beta-catenin by the destruction complex
R-HSA-5688426: Deubiquitination
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-5619115: Disorders of transmembrane transporters
R-HSA-202424: Downstream TCR signaling
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-1236974: ER-Phagosome pathway
R-HSA-8854050: FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2871837: FCERI mediated NF-kB activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-69615: G1/S DNA Damage Checkpoints
R-HSA-69206: G1/S Transition
R-HSA-69481: G2/M Checkpoints
R-HSA-69275: G2/M Transition
R-HSA-5610785: GLI3 is processed to GLI3R by the proteasome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-74160: Gene Expression
R-HSA-162906: HIV Infection
R-HSA-5610787: Hedgehog 'off' state
R-HSA-5632684: Hedgehog 'on' state
R-HSA-5358346: Hedgehog ligand biogenesis
R-HSA-5387390: Hh mutants abrogate ligand secretion
R-HSA-5362768: Hh mutants that don't undergo autocatalytic processing are degraded by ERAD
R-HSA-162909: Host Interactions of HIV factors
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-68886: M Phase
R-HSA-68874: M/G1 Transition
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-5687128: MAPK6/MAPK4 signaling
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-351202: Metabolism of polyamines
R-HSA-392499: Metabolism of proteins
R-HSA-68882: Mitotic Anaphase
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5676590: NIK-->noncanonical NF-kB signaling
R-HSA-6798695: Neutrophil degranulation
R-HSA-68949: Orc1 removal from chromatin
R-HSA-1234176: Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
R-HSA-4086400: PCP/CE pathway
R-HSA-597592: Post-translational protein modification
R-HSA-5357801: Programmed Cell Death
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-176408: Regulation of APC/C activators between G1/S and early anaphase
R-HSA-169911: Regulation of Apoptosis
R-HSA-69304: Regulation of DNA replication
R-HSA-1234174: Regulation of Hypoxia-inducible Factor (HIF) by oxygen
R-HSA-5658442: Regulation of RAS by GAPs
R-HSA-211733: Regulation of activated PAK-2p34 by proteasome mediated degradation
R-HSA-450531: Regulation of mRNA stability by proteins that bind AU-rich elements
R-HSA-453276: Regulation of mitotic cell cycle
R-HSA-350562: Regulation of ornithine decarboxylase (ODC)
R-HSA-69300: Removal of licensing factors from origins
R-HSA-69242: S Phase
R-HSA-187577: SCF(Skp2)-mediated degradation of p27/p21
R-HSA-174113: SCF-beta-TrCP mediated degradation of Emi1
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-5358351: Signaling by Hedgehog
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-195721: Signaling by Wnt
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-69541: Stabilization of p53
R-HSA-69052: Switching of origins to a post-replicative state
R-HSA-69239: Synthesis of DNA
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-202403: TCR signaling
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-8852276: The role of GTSE1 in G2/M progression after G2 checkpoint
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-5689603: UCH proteinases
R-HSA-5689880: Ub-specific processing proteases
R-HSA-69601: Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
R-HSA-75815: Ubiquitin-dependent degradation of Cyclin D
R-HSA-69229: Ubiquitin-dependent degradation of Cyclin D1
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-180585: Vif-mediated degradation of APOBEC3G
R-HSA-180534: Vpu mediated degradation of CD4
R-HSA-69563: p53-Dependent G1 DNA Damage Response
R-HSA-69580: p53-Dependent G1/S DNA damage checkpoint
R-HSA-69610: p53-Independent DNA Damage Response
R-HSA-69613: p53-Independent G1/S DNA damage checkpoint
Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PSMC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PSMC2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.59 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PSMC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0730.737
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3140.907
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1020.958
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0490.876
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.080.962
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0030.999
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1190.771
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3330.866
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1310.952
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.280.886
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4050.897
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1740.00286
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PSMC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PSMC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PSMC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PSMC2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PSMC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PSMC2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PSMC2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPSMC2
Nameproteasome 26S subunit, ATPase 2
Aliases Nbla10058; proteasome 26S subunit, ATPase, 2; mammalian suppressor of sgv-1 of yeast; protease 26S subunit 7 ......
Chromosomal Location7q22.1-q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PSMC2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.